|
FREE Newsletter Timely Market Commentary Daily Stock Picks News Analysis |
|
Company: Oxigene, Inc. OXGN
Price: 0.44
Change: +29.41%
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
__
TaxMasters, Inc. (OTC Bulletin Board: TAXS), the IRS tax relief company, recently reported the company’s financial results for the first quarter ended March 31, 2010. For the first quarter of 2010, TaxMasters net revenue increased 56.1% to approximately $11.3 million, compared to approximately $7.3 million for the first quarter of fiscal 2009. Total operating expenses for the first quarter of 2010 were approximately $9.9 million, an increase of 62.9% compared to $6.1 million for the same period in 2009. For the first quarter of 2010, the company reported net income from operations of approximately $1.5 million, an increase of approximately 20% compared to approximately $1.2 million for the same period in 2009. The increase was attributable to the increase in revenue offset by increases in compensation costs and advertising expenses. For the quarter ended March 31, 2010, the company reported net income of approximately $0.9 million, versus net income of approximately $1.2 million for the first quarter of fiscal 2009. The decrease in net income for the first quarter of 2010 compared to the same period in 2009 is mainly due to the tax expense of $0.5 million for the first quarter of 2010.
AGTC, a privately held company, and Icagen, Inc. (Nasdaq:ICGN) reported the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness. Icagen has retained an exclusive license for small molecule therapeutics targeting this gene. Pursuant to the transaction, AGTC will make a $1.0 million payment to Icagen.
ZelnickMedia and Alloy, Inc. (Nasdaq:ALOY) reported that an investor group led by ZelnickMedia has agreed to acquire Alloy for $9.80 per share in cash. The purchase price is a premium of approximately 27% over the average closing price of the stock for the 30 days ending June 23, 2010. The transaction is valued at approximately $126.5 million. Members of Alloy’s senior management will invest in the transaction in conjunction with ZelnickMedia.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic thyroid cancer (ATC), will be presented at the upcoming 14th International Thyroid Congress in Paris, France, on September 12, 2010. OXiGENE will release a summary of results immediately after they are presented.
**************************************************************
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received twenty four thousand dollars from Tax Masters Inc.(TAXS.OB) for 30 days of advertisement services. Crown Equity Holdings, Inc. (CRWE.OB) has received four thousand dollars from a third party (Marshall Curtis) for 30 days of advertisement for services for Tax Masters Inc.(TAXS.OB) which has expired. Crown Equity Holdings, Inc. has received an additional four thousand dollars from the same third party (Marshall Curtis) for an additional 30 days of advertisement services.
__
TaxMasters, Inc. (OTC Bulletin Board: TAXS), the IRS tax relief company, reported the company’s financial results for the first quarter ended March 31, 2010. For the first quarter of 2010, TaxMasters net revenue increased 56.1% to approximately $11.3 million, compared to approximately $7.3 million for the first quarter of fiscal 2009. Total operating expenses for the first quarter of 2010 were approximately $9.9 million, an increase of 62.9% compared to $6.1 million for the same period in 2009. For the first quarter of 2010, the company reported net income from operations of approximately $1.5 million, an increase of approximately 20% compared to approximately $1.2 million for the same period in 2009. The increase was attributable to the increase in revenue offset by increases in compensation costs and advertising expenses. For the quarter ended March 31, 2010, the company reported net income of approximately $0.9 million, versus net income of approximately $1.2 million for the first quarter of fiscal 2009. The decrease in net income for the first quarter of 2010 compared to the same period in 2009 is mainly due to the tax expense of $0.5 million for the first quarter of 2010.
SS&C Technologies Holdings, Inc. (Nasdaq:SSNC), a global provider of financial services software and software-enabled services, today previewed the release of CAMRA’s Impairments Manager at the IASA 2010 Annual Educational Conference and Business Show. The new functionality provides integrated support for the management of data collection, analysis, calculations and workflow surrounding impairment processing with a focus on GAAP and Regulatory guidance.
Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced results from Phase 1/2 clinical trials in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented during the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL. Yesterday’s presentation focused on two clinical trials, the 402 trial and the 403 trial. The 402 trial is a Phase 1/2, three arm, multicenter, dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine or docetaxel or pemetrexed in patients with advanced solid tumors. In the gemcitabine treatment arm, thirty-four patients with advanced or metastatic pancreatic cancer have had at least one evaluable post-treatment tumor assessment, including one patient (3%) with a complete response as measured by RECIST (Response Evaluation Criteria In Solid Tumors) and 8 patients (24%) with a partial response. Twenty-two patients (65%) achieved stable disease while 3 patients (9%) had progressive disease. Median progression free survival (PFS) was 6.4 months (95% CI: 4.3 months to Not Reached). Of the 34 assessed patients, 28 had elevated CA 19-9 levels at baseline and 17 of 28 (61%) had a CA19-9 reduction of greater than 50%. Hematologic toxicity was acceptable and skin and mucosal toxicities were well managed at current dose levels.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors. Data from a dose escalation study of 45 patients with advanced solid tumors who had declined or were refractory to standard treatment were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). Partial responses were observed in two patients with epithelial ovarian cancer and stable disease was observed in 9 patients. OXi4503 was also shown to be well-tolerated.
**************************************************************
********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received four thousand dollars from a third party (Marshall Curtis) for 30 days of advertisement for services for Tax Masters Inc.(TAXS.OB) which has expired. Crown Equity Holdings, Inc. has received an additional four thousand dollars from the same third party (Marshall Curtis) for an additional 30 days of advertisement services.
PennyToBuck.com Hot Stock News & Alerts!
FREE Daily Stock Alerts From PennyToBuck.com
Friday April 23, 2010
PennyToBuck.com Stock Report!
****************
HE-5 Resources Corp. (Other OTC: HRRN.PK) reported that the closed beta tests of the next version of its HE-Feed module are almost completed. Thus this component that was added in Mustang-Look on the 8th of April, will soon manage your social network accounts in real time. Since Facebook is the network most requested by HE-5’s clients, HE-5 Resources started with them, but obviously HE-Feed will accommodate in the future many other network feeds like Twitter and LinkedIn. Moreover, for the sake of consistency and efficiency, HE-5 will soon allow their subscribers to join its beta testers for the last test phase before the official launch. Up until now, the module HE-Feed allowed one to manage and track RSS feeds directly from your Mustang-Look account. At the introduction of the second version of this module, it will then also be possible to monitor and respond in real time with one’s personal or professional Facebook account. File and classify your contacts and status by categories (Follower, Friends, etc. …).Change your own status, information, directly through your Triple Crown CRM account. Manage your social networks with the same simplicity and security as your emails, contacts, tasks, calendars, and more, thanks to HE-Feed.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its first quarter 2010 financial results on Tuesday, May 4, 2010. Results will be released at the close of trading on that day.
Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced that it will issue its financial results of operations for its 2010 fiscal third quarter ended March 31, 2010 before the stock market opens on Friday, May 7, 2010. That morning at 10:00 am ET, Albert Eilender, Vincent Miata, and Douglas Roth will conduct a conference call.
Arcadia Capital Advisors Managing Director Richard Rofe announced today that he has commenced a $16.00 per share all-cash tender offer for CPEX Pharmaceuticals, Inc. (Nasdaq:CPEX) through RSR Acquisition Co., a wholly-owned subsidiary of Shelter Bay Holdings, LLC.
**************************************************************
***********Advertisement***********
.png)
.png)
.png)
********************************
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is anticipating fifteen thousand dollars in cash from a third party for 1 week of media advertisement services for HE-5 Resources Corp. (HRRN.PK)
HRRNcrwe0423
PennyOmega.com Hot Stock News & Alerts!
FREE Daily Stock Alerts From PennyOmega.com
Friday April 23, 2010
PennyOmega.com Stock Report!
*******************
HE-5 Resources Corp. (Other OTC: HRRN.PK) reported that the closed beta tests of the next version of its HE-Feed module are almost completed. Thus this component that was added in Mustang-Look on the 8th of April, will soon manage your social network accounts in real time. Since Facebook is the network most requested by HE-5’s clients, HE-5 Resources started with them, but obviously HE-Feed will accommodate in the future many other network feeds like Twitter and LinkedIn. Moreover, for the sake of consistency and efficiency, HE-5 will soon allow their subscribers to join its beta testers for the last test phase before the official launch. Up until now, the module HE-Feed allowed one to manage and track RSS feeds directly from your Mustang-Look account. At the introduction of the second version of this module, it will then also be possible to monitor and respond in real time with one’s personal or professional Facebook account. File and classify your contacts and status by categories (Follower, Friends, etc. …).Change your own status, information, directly through your Triple Crown CRM account. Manage your social networks with the same simplicity and security as your emails, contacts, tasks, calendars, and more, thanks to HE-Feed.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its first quarter 2010 financial results on Tuesday, May 4, 2010. Results will be released at the close of trading on that day.
Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced that it will issue its financial results of operations for its 2010 fiscal third quarter ended March 31, 2010 before the stock market opens on Friday, May 7, 2010. That morning at 10:00 am ET, Albert Eilender, Vincent Miata, and Douglas Roth will conduct a conference call.
Arcadia Capital Advisors Managing Director Richard Rofe announced today that he has commenced a $16.00 per share all-cash tender offer for CPEX Pharmaceuticals, Inc. (Nasdaq:CPEX) through RSR Acquisition Co., a wholly-owned subsidiary of Shelter Bay Holdings, LLC.
**************************************************************
***********Advertisement***********
********************************
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is anticipating fifteen thousand dollars in cash from a third party for 1 week of media advertisement services for HE-5 Resources Corp. (HRRN.PK)
HRRNcrwe0423
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Powered by WordPress
